Abstract Number: Esoc2026a1595 Combined Lipid-Lowering Therapy With Atorvastatin and Ezetimibe in Patients With Ishemic Stroke and Dyslipidemia: A Retrospectve Analysis

Abstract Background Ischemic stroke is a leading cause of mortality and long-term disability. Dyslipidemia is a major modifiable vascular risk factor. Intensive reduction of low-density lipoprotein cholesterol (LDL-C) is essential for secondary stroke prevention. Combined therapy with atorvastatin and ezetimibe targets complementary mechanisms of cholesterol metabolism, achieving greater LDL-C reduction compared to statin monotherapy. Aim To assess the effectiveness and tolerability of fixed-dose atorvastatin/ezetimibe therapy in patients with ischemic stroke and concomitant dyslipidemia in routine clinical practice. Methods This retrospective observational study included 130 patients with ischemic stroke and dyslipidemia treated with fixed-dose atorvastatin/ezetimibe at a tertiary neurology center between march 2023 and february 2024 – 12 months. Lipid parameters and neurological status were evaluated at baseline and during follow-up. Safety and tolerability were assessed using clinical and laboratory data. Results Treatment with atorvastatin/ezetimibe resulted in a statistically significant reduction in LDL-C levels during follow-up. Patients demonstrated improvement in neurological status and the therapy was well tolerated, with no clinically significant adverse events requiring treatment discontinuation. Conclusions In real-world clinical practice, fixed-dose atorvastatin/ezetimibe therapy is effective and safe in patients with ischemic stroke and dyslipidemia. These findings support its use as an intensive lipid-lowering strategy for secondary prevention in high-risk stroke patients. Conflict of interest Egis